Benzinga | May 6, 2021 08:55AM EDT

MIMEDX Announces Collaborative Agreement with the Wake Forest Institute for Regenerative Medicine

MIMEDX Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced a collaborative agreement with the Wake Forest Institute for Regenerative Medicine (WFIRM) to develop and advance scientific evidence in support of safe and effective clinical therapies. The partnership reflects a shared vision to advance regenerative science and innovative biologics that restore quality of life for patients, and is geared to further understanding product mechanisms of action and potential therapeutic targets.

Timothy R. Wright, MIMEDX Chief Executive Officer, commented, "We look forward to working with Dr. Anthony Atala and the Wake Forest Institute for Regenerative Medicine to positively impact patient care. The need for scientific advancement and peer-reviewed clinical data has never been greater, and together, I believe this partnership demonstrates our mutual commitment to evolving the science and technology that advances human health, and supporting the advancement of safe and effective treatment options for patients. As the leader in amniotic tissue science, we look forward to our collaboration with WFIRM to advance the next generation of therapies for a broad range of disease states."